COMPASS THERAPEUTICS INC. - COMMON STOCK

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

21 4 2025 08:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

02 4 2025 16:05:00 提供 Nasdaq GlobeNewswire

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

01 4 2025 07:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

31 3 2025 16:05:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

27 2 2025 08:00:01 提供 Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

29 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

08 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

10 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

02 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics to Participate in Upcoming Investor Events

13 11 2024 08:30:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

12 11 2024 08:00:02 提供 Nasdaq GlobeNewswire

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

08 11 2024 10:05:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

04 10 2024 10:31:45 提供 Nasdaq GlobeNewswire

Compass Therapeutics to Participate in Upcoming Investor Events

03 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

12 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

07 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer

06 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

30 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Compass Therapeutics Announces CEO Transition

28 5 2024 16:10:20 提供 Nasdaq GlobeNewswire

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

23 5 2024 17:05:00 提供 Nasdaq GlobeNewswire